Drug Profile

212 Pb ADVC 001

Alternative Names: 212-lead ADVC 001; ²¹²Pb ADVC001; [212Pb]Pb-ADVC001

Latest Information Update: 27 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Advancell
Class Antineoplastics; Lead radioisotopes; Radiopharmaceuticals; Small molecules
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Prostate cancer

Most Recent Events

18 Oct 2025 Adverse events, efficacy and pharmacokinetics data from a phase Ib/IIa TheraPb in Prostate cancer released by Advancell
12 Oct 2025 AdvanCell has patent protection for 212 Pb ADVC 001
25 Apr 2025 Pharmacodynamics data from a preclinical trial in Prostate cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com